- Home
- RANI vs CTMX Comparison
RANI vs CTMX Comparison
Compare RANI & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RANI
- CTMX
- Stock Information
- Founded
- RANI 2012
- CTMX 2008
- Country
- RANI United States
- CTMX United States
- Employees
- RANI N/A
- CTMX N/A
- Industry
- RANI Medicinal Chemicals and Botanical Products
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- RANI Health Care
- CTMX Health Care
- Exchange
- RANI Nasdaq
- CTMX Nasdaq
- Market Cap
- RANI 55.3M
- CTMX 62.3M
- IPO Year
- RANI 2021
- CTMX 2015
- Fundamental
- Price
- RANI $1.23
- CTMX $0.58
- Analyst Decision
- RANI Strong Buy
- CTMX Buy
- Analyst Count
- RANI 6
- CTMX 6
- Target Price
- RANI $11.33
- CTMX $5.77
- AVG Volume (30 Days)
- RANI 145.5K
- CTMX 3.8M
- Earning Date
- RANI 03-31-2025
- CTMX 03-06-2025
- Dividend Yield
- RANI N/A
- CTMX N/A
- EPS Growth
- RANI N/A
- CTMX N/A
- EPS
- RANI N/A
- CTMX 0.38
- Revenue
- RANI N/A
- CTMX $138,103,000.00
- Revenue This Year
- RANI N/A
- CTMX N/A
- Revenue Next Year
- RANI N/A
- CTMX N/A
- P/E Ratio
- RANI N/A
- CTMX $1.57
- Revenue Growth
- RANI N/A
- CTMX 36.45
- 52 Week Low
- RANI $1.20
- CTMX $0.56
- 52 Week High
- RANI $8.75
- CTMX $5.85
- Technical
- Relative Strength Index (RSI)
- RANI 33.72
- CTMX 37.64
- Support Level
- RANI $1.30
- CTMX $0.57
- Resistance Level
- RANI $1.56
- CTMX $0.65
- Average True Range (ATR)
- RANI 0.09
- CTMX 0.05
- MACD
- RANI -0.03
- CTMX 0.00
- Stochastic Oscillator
- RANI 8.33
- CTMX 15.04
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.